During the past decade, Sykehuset Østfold Kalnes; Onkologisk seksjon conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 1 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Sykehuset Østfold Kalnes; Onkologisk seksjon" are "Metastatic Breast Cancer" (1 trials) and "Metastatic Prostate Cancer" (1 trials). Many other conditions were trialed in "Sykehuset Østfold Kalnes; Onkologisk seksjon" in a lesser frequency.

Most popular intervention types in "Sykehuset Østfold Kalnes; Onkologisk seksjon" are "Drug" (2 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Abiraterone" (1 trials), "Atezolizumab" (1 trials), "Ipatasertib" (1 trials) and "Prednisone/Prednisolone" (1 trials). Other intervention names were less common.

The vast majority of trials in "Sykehuset Østfold Kalnes; Onkologisk seksjon" are 1 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Sykehuset Østfold Kalnes; Onkologisk seksjon". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Sykehuset Østfold Kalnes; Onkologisk seksjon, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Sykehuset Østfold Kalnes; Onkologisk seksjon, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".